Companies › EnnovaBio
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Other, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ENN0403 | – | Phase 2 | Diabetic Macular Edema (DME) | – |
| ENC0653 | – | Phase 1 | Healthy | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06708260 | ENN0403 | Phase 2 | Diabetic Macular Edema (DME) | Ophthalmology | Aug 2026 |
| NCT07684196 | ENC0653 | Phase 1 | Healthy | Other | Dec 2026 |
No annotated target.
–
Atsena Therapeutics PolyActiva Tortugas Neuroscience Ashvattha Therapeutics Vantage Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.